A related editorial discusses the findings of this study, in the context of the CONFIRM study which compared standard letrozole alone with letrozole in combination with a CDK4 or CDK6 inhibitor highlighting that besides the clinical criteria, several additional factors should be considered when selecting the appropriate endocrine therapy, including the access to novel drugs based on regional regulatory availability, and the additional toxicity and higher costs typically associated with the combination regimens.